

Monika Engelhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7374622/publications.pdf>

Version: 2024-02-01

169
papers

5,173
citations

101384

36
h-index

106150

65
g-index

172
all docs

172
docs citations

172
times ranked

5655
citing authors

#	ARTICLE	IF	CITATIONS
1	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
2	Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1045-1055.	1.2	7
3	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	2.2	44
4	Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 55.	1.7	12
5	Proteasome inhibition: the dawn of novel therapies in multiple myeloma. <i>Haematologica</i> , 2022, 107, 1018-1019.	1.7	2
6	Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. <i>Haematologica</i> , 2021, 106, 875-880.	1.7	14
7	Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs. <i>Leukemia and Lymphoma</i> , 2021, 62, 891-898.	0.6	4
8	Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e160-e175.	0.2	31
9	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 521-530.	0.5	12
10	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	3.3	35
11	Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. <i>BMC Nephrology</i> , 2021, 22, 32.	0.8	14
12	Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. <i>Journal of Medical Economics</i> , 2021, 24, 114-122.	1.0	7
13	Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. <i>BMC Cancer</i> , 2021, 21, 173.	1.1	3
14	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
15	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. <i>Annals of Hematology</i> , 2021, 100, 1637-1640.	0.8	1
16	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSM. <i>Cancers</i> , 2021, 13, 1322.	1.7	6
17	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021, 22, e105-e118.	5.1	136
18	In search of the optimal proteasome inhibitor. How, when and for whom?. <i>Haematologica</i> , 2021, 106, 2539-2541.	1.7	0

#	ARTICLE	IF	CITATIONS
19	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
20	Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. <i>Cancer</i> , 2021, 127, 3422-3436.	2.0	9
21	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	2.0	4
22	Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience. <i>HemaSphere</i> , 2021, 5, e597.	1.2	4
23	Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILE study. <i>Supportive Care in Cancer</i> , 2021, 29, 8045-8057.	1.0	15
24	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
25	Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 708231.	1.3	7
26	Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 529-542.	1.1	3
27	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. <i>Cancers</i> , 2021, 13, 4320.	1.7	11
28	Geriatric assessments and frailty scores in multiple myeloma patients. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 648-657.	1.1	16
29	Elektronische Verordnungssysteme in der Hämatologie und Onkologie/CPOE. <i>Springer Reference Medizin</i> , 2021, , 1-8.	0.0	0
30	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 4327-4337.	2.5	9
31	Targeting mitotic exit in solid tumors. <i>American Journal of Cancer Research</i> , 2021, 11, 3698-3710.	1.4	0
32	Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial. <i>Blood</i> , 2021, 138, 1662-1662.	0.6	2
33	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
34	Dynamic prediction: A challenge for biostatisticians, but greatly needed by patients, physicians and the public. <i>Biometrical Journal</i> , 2020, 62, 822-835.	0.6	10
35	Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia. <i>Haematologica</i> , 2020, 105, 1285-1293.	1.7	22
36	Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. <i>Haematologica</i> , 2020, 105, e138-e140.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective –Deutsche Studiengruppe MM–™ (DSMM) and –European Myeloma Network–™ (EMN) analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 875-886.	0.6	12
38	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. <i>Leukemia Research</i> , 2020, 98, 106454.	0.4	8
39	Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e821-e825.	0.2	2
40	Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. <i>Cancer Medicine</i> , 2020, 9, 8412-8422.	1.3	29
41	COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1264-1266.	1.4	27
42	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	1.7	40
43	Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients. <i>Cancer</i> , 2020, 126, 3504-3515.	2.0	18
44	Defining the vulnerable patient with myeloma – a frailty position paper of the European Myeloma Network. <i>Leukemia</i> , 2020, 34, 2285-2294.	3.3	45
45	Clinicians and patients perspectives on follow-up care and eHealth support after allogeneic hematopoietic stem cell transplantation: A mixed-methods contextual analysis as part of the SMILE study. <i>European Journal of Oncology Nursing</i> , 2020, 45, 101723.	0.9	37
46	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 764-768.	0.5	26
47	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. <i>Haematologica</i> , 2020, 105, 1183-1188.	1.7	46
48	Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment. <i>Haematologica</i> , 2020, 105, 859-861.	1.7	7
49	Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. <i>Haematologica</i> , 2020, 105, e523.	1.7	10
50	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
51	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 199-206.	0.7	1
52	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	3.3	28
53	Avoiding chemotherapy prescribing errors: Analysis and innovative strategies. <i>Cancer</i> , 2019, 125, 1547-1557.	2.0	19
54	Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. <i>European Journal of Haematology</i> , 2019, 103, 255-267.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
56	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?. <i>Haematologica</i> , 2019, 104, 2128-2131.	1.7	3
57	Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis. <i>Hemodialysis International</i> , 2019, 23, E59-E64.	0.4	4
58	APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 369-380.	2.4	5
59	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. <i>Haematologica</i> , 2019, 104, 370-379.	1.7	53
60	Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study. <i>Blood</i> , 2019, 134, 3480-3480.	0.6	3
61	The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability. <i>Blood</i> , 2019, 134, 3474-3474.	0.6	4
62	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit) <i>Tj ETQq0 0 0 rgBT7/Overloadz 10 Tf 50</i>		
63	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , 2018, 124, 2075-2085.	2.0	49
64	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
65	Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae. <i>Annals of Hematology</i> , 2018, 97, 1497-1500.	0.8	1
66	Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 2692-2699.	0.6	19
67	Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. <i>Leukemia and Lymphoma</i> , 2018, 59, 1722-1725.	0.6	4
68	Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e1-e7.	0.2	6
69	Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. <i>Supportive Care in Cancer</i> , 2018, 26, 833-841.	1.0	14
70	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
71	Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. <i>Haematologica</i> , 2018, 103, 755-758.	1.7	6
72	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86

#	ARTICLE	IF	CITATIONS
73	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
74	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81
75	Carfilzomib. <i>Recent Results in Cancer Research</i> , 2018, 212, 265-283.	1.8	2
76	Pomalidomide. <i>Recent Results in Cancer Research</i> , 2018, 212, 169-185.	1.8	6
77	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
78	Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study. <i>Blood</i> , 2018, 132, 2288-2288.	0.6	4
79	Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. <i>Leukemia and Lymphoma</i> , 2017, 58, 1849-1858.	0.6	13
80	Is immunotherapy here to stay in multiple myeloma?. <i>Haematologica</i> , 2017, 102, 423-432.	1.7	42
81	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. <i>Haematologica</i> , 2017, 102, 910-921.	1.7	187
82	Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 484-493.	2.3	10
83	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394
84	Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. <i>British Journal of Haematology</i> , 2017, 179, 586-597.	1.2	30
85	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. <i>European Journal of Haematology</i> , 2017, 99, 449-458.	1.1	6
86	CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 36-49.	1.2	63
87	Elderly patients with multiple myeloma: towards a frailty approach?. <i>Current Opinion in Oncology</i> , 2017, 29, 315-321.	1.1	77
88	Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML <i>in vitro</i> and prolongs survival <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 21153-21166.	0.8	15
89	Avoiding Errors in Chemotherapy. <i>Deutsches Ärzteblatt International</i> , 2017, 114, 224.	0.6	0
90	Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?. <i>Haematologica</i> , 2016, 101, 1276-1278.	1.7	10

#	ARTICLE	IF	CITATIONS
91	Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. <i>Haematologica</i> , 2016, 101, 1110-1119.	1.7	145
92	From <scp>CLL</scp> to Multiple Myeloma â€•Spleen Tyrosine Kinase (<scp>SYK</scp>) influences multiple myeloma cell survival and migration. <i>British Journal of Haematology</i> , 2016, 174, 985-989.	1.2	8
93	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	1.9	28
94	Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 48220-48230.	0.8	8
95	Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis. <i>Blood</i> , 2016, 128, 5979-5979.	0.6	0
96	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. <i>Haematologica</i> , 2015, 100, 1340-1349.	1.7	43
97	Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia. <i>Mycoses</i> , 2015, 58, 76-81.	1.8	1
98	Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. <i>Clinical Cancer Research</i> , 2015, 21, 1530-1536.	3.2	157
99	Analysis of survival by tumor response: have we learnt any better?. <i>Annals of Hematology</i> , 2015, 94, 1615-1616.	0.8	7
100	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
101	Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD). <i>Blood</i> , 2015, 126, 4260-4260.	0.6	1
102	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	1.7	124
103	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	1.7	185
104	Multiple Myeloma and Second Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 98-101.	0.2	6
105	Pomalidomide. <i>Recent Results in Cancer Research</i> , 2014, 201, 359-372.	1.8	11
106	Final Results from the Phase IIa Study of the Anti-CXCL12 SpiegelmerÂ® Olaptosed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2111-2111.	0.6	4
107	Exosomes Secreted By Multiple Myeloma Cell Lines (MMCLs) and Bone Marrow Stromal Cells (BMSCs) Reciprocally Modulate Cell Adhesion and Impact on MM Cell Migration and Bortezomib-Induced Apoptosis. <i>Blood</i> , 2014, 124, 5141-5141.	0.6	1
108	Prevalence of Iron Overload Vs Iron Deficiency in Multiple Myeloma: Resembling or Different From MDSâ€™ and Stem Cell Transplant (SCT)â€™Patients?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 671-680.e3.	0.2	12

#	ARTICLE	IF	CITATIONS
109	Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 541-551.	0.2	72
110	Posaconazole Therapeutic Drug Monitoring in the Real-life Setting: A Single-Center Experience and Review of the Literature. <i>Pharmacotherapy</i> , 2013, 33, 1117-1125.	1.2	34
111	Preclinical models of multiple myeloma: a critical appraisal. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S111-S123.	1.4	21
112	Cytogenetics of extramedullary manifestations in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 87-94.	1.2	81
113	Potent <i>in vitro</i> and <i>in vivo</i> activity of sorafenib in multiple myeloma: induction of cell death, $CD138$ downregulation and inhibition of migration through actin depolymerization. <i>British Journal of Haematology</i> , 2013, 161, 104-116.	1.2	40
114	Anti-CXCL12/SDF-1 Spiegelmer [®] Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study. <i>Blood</i> , 2013, 122, 1951-1951.	0.6	3
115	Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial. <i>Blood</i> , 2013, 122, 1987-1987.	0.6	13
116	The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells. <i>PLoS ONE</i> , 2013, 8, e74379.	1.1	6
117	Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2R ³ (Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies. <i>PLoS ONE</i> , 2013, 8, e79939.	1.1	23
118	The Tumor Suppressor APC/CCdh1 and Its Role In Replication Stress and The Origin Of Genomic Instability. <i>Blood</i> , 2013, 122, 2489-2489.	0.6	1
119	Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1057-1061.	0.6	11
120	Prognostic Risk Factor Evaluation in Patients With Relapsed or Refractory Multiple Myeloma Receiving Lenalidomide Treatment: Analysis of Renal Function by eGFR and of Additional Comorbidities by Comorbidity Appraisal. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 38-48.	0.2	26
121	Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. <i>Annals of Hematology</i> , 2012, 91, 1579-1586.	0.8	27
122	Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 953-963.	0.9	9
123	Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. <i>Annals of Hematology</i> , 2012, 91, 287-289.	0.8	19
124	Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. <i>Anticancer Research</i> , 2012, 32, 2031-4.	0.5	18
125	Management of Multiple Myeloma in Pregnancy: Strategies for a Rare Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 190-197.	0.2	21
126	Early and mature endothelial progenitors and VEGFR2+ cells in multiple myeloma: Association with disease characteristics and variation in different cell compartments. <i>Leukemia Research</i> , 2011, 35, 1265-1268.	0.4	8

#	ARTICLE	IF	CITATIONS
127	Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 247-259.	0.6	63
128	Does Colorectal Cancer in Ulcerative Colitis Patients Constitute a Risk for Chemotherapy Refractoriness? A Systemic Approach by Detailed Analysis via the Electronic Tumor Base Documentation System. <i>Onkologie</i> , 2011, 34, 688-694.	1.1	3
129	Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4029-4032.	1.4	28
130	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	0.6	14
131	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	0.6	49
132	Rituximab Plus Bendamustine (R-B) Treatment In Patients with Aggressive Large B-Cell Lymphoma (LBCL): Response and Tolerability - a Single Institution Experience. <i>Blood</i> , 2010, 116, 4900-4900.	0.6	1
133	Ordering Errors Were Identified. <i>Deutsches A&#x0308;rzteblatt International</i> , 2010, 107, 557-8; author reply 559-60.	0.6	1
134	Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. <i>European Journal of Haematology</i> , 2009, 83, 519-527.	1.1	67
135	Chemotherapy safety and severe adverse events in cancer patients: Strategies to efficiently avoid chemotherapy errors in inpatient and outpatient treatment. <i>International Journal of Cancer</i> , 2009, 124, 722-728.	2.3	85
136	Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2493-2498.	1.2	26
137	Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).. <i>Blood</i> , 2009, 114, 131-131.	0.6	27
138	Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain ^{-/-} (NSG) Mice Using an Intratibial Tumor Dissemination approach. <i>Blood</i> , 2009, 114, 4912-4912.	0.6	1
139	Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma - An Interim Analysis of the German DSMM V Trial.. <i>Blood</i> , 2009, 114, 51-51.	0.6	19
140	In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.. <i>Blood</i> , 2009, 114, 4922-4922.	0.6	0
141	Invasive Mycoses in High-Risk Cancer Patients - a Prospective Analysis of Clinical Parameters, Side Effects, Drug Interactions and Costs for the Safe and Economically Appropriate Use of Systemic Antifungal Agents.. <i>Blood</i> , 2009, 114, 2487-2487.	0.6	0
142	Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.. <i>Blood</i> , 2009, 114, 4945-4945.	0.6	0
143	Downregulation of the Cell-Cycle Regulating Ubiquitin-Ligase APC/CCdh1 May Contribute to the Differentiation Block of AML1/Eto Positive AML.. <i>Blood</i> , 2009, 114, 5045-5045.	0.6	0
144	Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. <i>Anticancer Research</i> , 2009, 29, 4745-50.	0.5	11

#	ARTICLE	IF	CITATIONS
145	Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey. <i>Blood</i> , 2008, 112, 2775-2775.	0.6	7
146	Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial. <i>Blood</i> , 2008, 112, 2776-2776.	0.6	3
147	Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 774-774.	0.6	5
148	Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines. <i>Blood</i> , 2008, 112, 1313-1313.	0.6	0
149	Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients. <i>Blood</i> , 2008, 112, 2372-2372.	0.6	0
150	Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2008, 112, 974-974.	0.6	0
151	Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: A single center analysis and review of the literature. <i>Leukemia and Lymphoma</i> , 2007, 48, 2255-2260.	0.6	7
152	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 138, 330-337.	1.2	156
153	Characterization of in vitro growth of multiple myeloma cells. <i>Experimental Hematology</i> , 2007, 35, 1550-1561.	0.2	42
154	Bortezomib Retreatment in Relapsed Multiple Myeloma - A Retrospective Multicenter Survey.. <i>Blood</i> , 2007, 110, 2720-2720.	0.6	1
155	A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 4830-4830.	0.6	2
156	Efficacy and Tolerability of Lenalidomide/Dexamethasone in Intensively Pretreated Myeloma Patients: Experiences from the German Named Patient Program.. <i>Blood</i> , 2007, 110, 4834-4834.	0.6	0
157	Intensive Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation During a 10-Year Period in 64 Patients with Germ Cell Tumor. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 355-365.	2.0	7
158	State of the art therapy in multiple myeloma and future perspectives. <i>European Journal of Cancer</i> , 2006, 42, 1591-1600.	1.3	30
159	160 years of multiple myeloma: Progress and challenges. <i>European Journal of Cancer</i> , 2006, 42, 1507-1509.	1.3	11
160	Primary (AL) Amyloidosis in Plasma Cell Disorders. <i>Oncologist</i> , 2006, 11, 824-830.	1.9	28
161	Coincidence of Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) in One Patient: An Exceptional or Common Event? Summary of 4 Cases at a Single Center.. <i>Blood</i> , 2006, 108, 4980-4980.	0.6	2
162	Improved Prediction of Kidney Disease by Estimating Renal Function: Use in Multiple Myeloma Patients Treated with Standard Versus High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5497-5497.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Assessment of the Culture Requirements for Optimal In Vitro Growth and Survival of Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3513-3513.	0.6	0
164	Peripheral Blood, Cord Blood and Bone Marrow Cells Sorted into SP+, CD34+ and SP ⁺ Cells Are Distinct in Their ABCG2 and MDR1 Expression Levels, Which Are Most Increased in SP+ Cells and Substantially Decline after In Vitro Culture and Terminal Cell Differentiation.. Blood, 2006, 108, 4154-4154.	0.6	0
165	Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica, 2006, 91, 274-6.	1.7	9
166	Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies.. Blood, 2005, 106, 2250-2250.	0.6	0
167	Dose Reduction of Thalidomide in Multiple Myeloma: A Feasible Option without Reducing of Efficacy.. Blood, 2005, 106, 5129-5129.	0.6	1
168	High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection. Journal of Clinical Oncology, 1999, 17, 2160-2160.	0.8	86
169	Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience. British Journal of Haematology, 0, , .	1.2	1